Drugs / β-hydroxy-β-methylbutyrate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07589764 | Oct 2026 → Oct 2027 expected | amyotrophic lateral sclerosis | Duke University | Not yet recruiting | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01607879 | Mar 2014 → Jul 2018 | prostate cancer | Medical College of Wisconsin | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | β-hydroxy-β-methylbutyrate | “Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation” NCT01607879 ↗ |
| Known as | HMB | “β-hydroxy-β-methylbutyrate (HMB)” NCT07589764 ↗ |